JP2022121461A - 抗met抗体とその利用 - Google Patents
抗met抗体とその利用 Download PDFInfo
- Publication number
- JP2022121461A JP2022121461A JP2022093880A JP2022093880A JP2022121461A JP 2022121461 A JP2022121461 A JP 2022121461A JP 2022093880 A JP2022093880 A JP 2022093880A JP 2022093880 A JP2022093880 A JP 2022093880A JP 2022121461 A JP2022121461 A JP 2022121461A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- met
- antigen
- human
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 claims abstract description 353
- 241000282414 Homo sapiens Species 0.000 claims abstract description 311
- 239000000556 agonist Substances 0.000 claims abstract description 67
- 239000000427 antigen Substances 0.000 claims description 247
- 108091007433 antigens Proteins 0.000 claims description 245
- 102000036639 antigens Human genes 0.000 claims description 245
- 239000012634 fragment Substances 0.000 claims description 224
- 210000004027 cell Anatomy 0.000 claims description 155
- 108010066733 mRNA (guanine(N7))-methyltransferase Proteins 0.000 claims description 150
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 145
- 102000057421 human MET Human genes 0.000 claims description 127
- 150000001413 amino acids Chemical class 0.000 claims description 73
- 101100291013 Mus musculus Met gene Proteins 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 69
- 125000000539 amino acid group Chemical group 0.000 claims description 64
- 238000003556 assay Methods 0.000 claims description 62
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 47
- 241000282842 Lama glama Species 0.000 claims description 41
- 238000002965 ELISA Methods 0.000 claims description 40
- 230000026731 phosphorylation Effects 0.000 claims description 37
- 238000006366 phosphorylation reaction Methods 0.000 claims description 37
- 206010067125 Liver injury Diseases 0.000 claims description 26
- 230000036755 cellular response Effects 0.000 claims description 25
- 230000024799 morphogenesis of a branching structure Effects 0.000 claims description 23
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 23
- 230000004913 activation Effects 0.000 claims description 22
- 206010012601 diabetes mellitus Diseases 0.000 claims description 22
- 108010053292 macrophage stimulating protein Proteins 0.000 claims description 20
- 102000049853 macrophage stimulating protein Human genes 0.000 claims description 20
- 210000005260 human cell Anatomy 0.000 claims description 17
- 230000006870 function Effects 0.000 claims description 16
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 16
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 16
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 15
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 230000029663 wound healing Effects 0.000 claims description 14
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 12
- 230000006698 induction Effects 0.000 claims description 12
- 230000036961 partial effect Effects 0.000 claims description 12
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 11
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 10
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 10
- 230000003833 cell viability Effects 0.000 claims description 7
- 239000012636 effector Substances 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 206010061481 Renal injury Diseases 0.000 claims description 5
- 230000001747 exhibiting effect Effects 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 231100000234 hepatic damage Toxicity 0.000 claims description 2
- 230000008818 liver damage Effects 0.000 claims description 2
- 230000004987 nonapoptotic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 abstract description 128
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract description 128
- 241000699670 Mus sp. Species 0.000 abstract description 115
- 230000001270 agonistic effect Effects 0.000 abstract description 61
- 230000000694 effects Effects 0.000 abstract description 52
- 241000282412 Homo Species 0.000 abstract description 27
- 238000011282 treatment Methods 0.000 abstract description 25
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 12
- 230000001225 therapeutic effect Effects 0.000 abstract description 12
- 101000898036 Mus musculus Hepatocyte growth factor Proteins 0.000 abstract description 2
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 154
- 235000001014 amino acid Nutrition 0.000 description 91
- 229940024606 amino acid Drugs 0.000 description 75
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 70
- 241000282832 Camelidae Species 0.000 description 58
- 210000004369 blood Anatomy 0.000 description 58
- 239000008280 blood Substances 0.000 description 58
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 51
- 238000004458 analytical method Methods 0.000 description 49
- 210000004185 liver Anatomy 0.000 description 46
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 41
- 239000008103 glucose Substances 0.000 description 41
- 108090000765 processed proteins & peptides Proteins 0.000 description 39
- 230000001965 increasing effect Effects 0.000 description 38
- 102000004196 processed proteins & peptides Human genes 0.000 description 37
- 229920001184 polypeptide Polymers 0.000 description 36
- 102000004877 Insulin Human genes 0.000 description 35
- 108090001061 Insulin Proteins 0.000 description 35
- 229940125396 insulin Drugs 0.000 description 35
- 241000282567 Macaca fascicularis Species 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 33
- 102000009203 Sema domains Human genes 0.000 description 32
- 108050000099 Sema domains Proteins 0.000 description 32
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 29
- 238000010172 mouse model Methods 0.000 description 29
- 238000006467 substitution reaction Methods 0.000 description 28
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 28
- 210000004602 germ cell Anatomy 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 26
- 210000001072 colon Anatomy 0.000 description 25
- 239000007924 injection Substances 0.000 description 23
- 238000002347 injection Methods 0.000 description 23
- 239000002953 phosphate buffered saline Substances 0.000 description 23
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 22
- 230000009260 cross reactivity Effects 0.000 description 22
- 239000007928 intraperitoneal injection Substances 0.000 description 22
- 241000894007 species Species 0.000 description 22
- 238000011887 Necropsy Methods 0.000 description 21
- 230000011664 signaling Effects 0.000 description 21
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 19
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 19
- 241000700159 Rattus Species 0.000 description 19
- 101100401310 Rattus norvegicus Met gene Proteins 0.000 description 19
- 239000003981 vehicle Substances 0.000 description 19
- 108060003951 Immunoglobulin Proteins 0.000 description 18
- 102000018358 immunoglobulin Human genes 0.000 description 18
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 17
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 17
- 108010082126 Alanine transaminase Proteins 0.000 description 17
- 238000011725 BALB/c mouse Methods 0.000 description 17
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 16
- 230000004190 glucose uptake Effects 0.000 description 16
- 230000004761 fibrosis Effects 0.000 description 15
- 230000003053 immunization Effects 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 210000000130 stem cell Anatomy 0.000 description 15
- 210000001339 epidermal cell Anatomy 0.000 description 14
- 239000012188 paraffin wax Substances 0.000 description 14
- 230000036470 plasma concentration Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 241000282693 Cercopithecidae Species 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 206010016654 Fibrosis Diseases 0.000 description 13
- 241001529936 Murinae Species 0.000 description 13
- 238000012217 deletion Methods 0.000 description 13
- 230000037430 deletion Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 13
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 102000057308 human HGF Human genes 0.000 description 12
- 239000007790 solid phase Substances 0.000 description 12
- 229960001052 streptozocin Drugs 0.000 description 12
- 241000282838 Lama Species 0.000 description 11
- 241000700157 Rattus norvegicus Species 0.000 description 11
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 11
- 238000007446 glucose tolerance test Methods 0.000 description 11
- 210000003494 hepatocyte Anatomy 0.000 description 11
- 230000003389 potentiating effect Effects 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 230000035578 autophosphorylation Effects 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 206010022489 Insulin Resistance Diseases 0.000 description 9
- 101100230981 Mus musculus Hgf gene Proteins 0.000 description 9
- 208000033626 Renal failure acute Diseases 0.000 description 9
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- 201000011040 acute kidney failure Diseases 0.000 description 9
- 231100000012 chronic liver injury Toxicity 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 231100000240 steatosis hepatitis Toxicity 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 description 8
- 206010019708 Hepatic steatosis Diseases 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 230000035987 intoxication Effects 0.000 description 8
- 231100000566 intoxication Toxicity 0.000 description 8
- 230000003278 mimic effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 231100000439 acute liver injury Toxicity 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 208000010706 fatty liver disease Diseases 0.000 description 7
- 238000010562 histological examination Methods 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- 229950000846 onartuzumab Drugs 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 208000004930 Fatty Liver Diseases 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000002306 biochemical method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 231100000753 hepatic injury Toxicity 0.000 description 6
- 229940072221 immunoglobulins Drugs 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 241001416177 Vicugna pacos Species 0.000 description 5
- 208000012998 acute renal failure Diseases 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000005239 tubule Anatomy 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 206010063836 Atrioventricular septal defect Diseases 0.000 description 4
- 206010057669 Colon injury Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 238000001211 electron capture detection Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 239000004031 partial agonist Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000005180 public health Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 208000007788 Acute Liver Failure Diseases 0.000 description 3
- 206010000804 Acute hepatic failure Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- 102000009161 IPT domains Human genes 0.000 description 3
- 108050000019 IPT domains Proteins 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 101150046735 LEPR gene Proteins 0.000 description 3
- 101150063827 LEPROT gene Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 231100000836 acute liver failure Toxicity 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 230000004709 cell invasion Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 235000020937 fasting conditions Nutrition 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 230000000803 paradoxical effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101710095342 Apolipoprotein B Proteins 0.000 description 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000282339 Mustela Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 206010038063 Rectal haemorrhage Diseases 0.000 description 2
- 102000014105 Semaphorin Human genes 0.000 description 2
- 108050003978 Semaphorin Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000001609 comparable effect Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 150000002303 glucose derivatives Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 108010019813 leptin receptors Proteins 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000921 morphogenic effect Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 231100000272 reduced body weight Toxicity 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000037309 reepithelialization Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 101100291001 Canis lupus familiaris MET gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101150022655 HGF gene Proteins 0.000 description 1
- 102000027430 HGF receptors Human genes 0.000 description 1
- 108091008603 HGF receptors Proteins 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 101000746783 Homo sapiens Cytochrome b-c1 complex subunit 6, mitochondrial Proteins 0.000 description 1
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000282852 Lama guanicoe Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 101100060131 Mus musculus Cdk5rap2 gene Proteins 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 241000282840 Vicugna vicugna Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229960003920 ***e Drugs 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000043381 human DUSP5 Human genes 0.000 description 1
- 102000048638 human UQCRH Human genes 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000002621 immunoprecipitating effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003903 intestinal lesions Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010085203 methionylmethionine Proteins 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002384 proinvasive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000010024 tubular injury Effects 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
Abstract
Description
(i)細胞散乱アッセイにおいて、この抗体またはその抗原結合フラグメントが、0.1~1.0 nMの濃度で、HGFが誘導する最大の散乱に匹敵する細胞散乱を誘導すること;
(ii)抗アポトーシス細胞アッセイにおいて、この抗体またはその抗原結合フラグメントが、HGFの値の1.1倍未満のEC50および/またはHGFで観察される値の90%超の(非アポトーシス対照細胞の全ATP含量に対する%として測定される)Emaxを示すこと;
(iii)分岐形態形成アッセイにおいて、この抗体で処理した細胞が、同じ(ゼロでない)濃度のHGFによって誘導されるスフェロイド当たりの分岐の数の90%超を示すこと
のうちの1つ、または任意の2つ、またはすべてとして可能である。
(i)細胞散乱アッセイにおいて、この抗体またはその抗原結合フラグメントが、1 nM以下の濃度で、0.1 nMの相同なHGFによって誘導される細胞散乱の少なくとも25%の細胞散乱を誘導すること;および/または
(ii)抗アポトーシス細胞アッセイにおいて、この抗体またはその抗原結合フラグメントが、HGFの値の7.0倍以下のEC50および/またはHGFで観察される値の少なくとも50%のEmax細胞生存率を示すこと、および/または;
(iii)分岐形態形成アッセイにおいて、この抗体で処理した細胞が、同じ(ゼロでない)濃度のHGFによって誘導されるスフェロイド当たりの分岐の数の少なくとも25%を示すこと
として可能である。
H-CDR1は、配列番号2、9、16、23、30、37、44、51、58、65、72から選択されたアミノ酸配列を含んでおり;
H-CDR2は、配列番号4、11、18、25、32、39、46、53、60、67、74から選択されたアミノ酸配列を含んでおり;
H-CDR3は、配列番号6、13、20、27、34、41、48、55、62、69、76から選択されたアミノ酸配列を含んでおり;
L-CDR1は、配列番号79、86、93、100、107、114、121、128、135、142、149から選択されたアミノ酸配列を含んでおり;
L-CDR2は、配列番号81、88、95、102、109、116、123、130、137、144、151から選択されたアミノ酸配列を含んでおり;
L-CDR3は、配列番号83、90、97、104、111、118、125、132、139、146、153から選択されたアミノ酸配列を含んでいる抗体またはその抗原結合フラグメントが提供される。
H-CDR1は、配列番号44として示すアミノ酸配列を含んでおり;
H-CDR2は、配列番号46として示すアミノ酸配列を含んでおり;
H-CDR3は、配列番号48として示すアミノ酸配列を含んでおり;
L-CDR1は、配列番号121として示すアミノ酸配列を含んでおり;
L-CDR2は、配列番号123として示すアミノ酸配列を含んでおり;
L-CDR3は、配列番号125として示すアミノ酸配列を含んでいる抗体またはその抗原結合フラグメントが提供される。
H-CDR1は、配列番号30として示すアミノ酸配列を含んでおり;
H-CDR2は、配列番号32として示すアミノ酸配列を含んでおり;
H-CDR3は、配列番号34として示すアミノ酸配列を含んでおり;
L-CDR1は、配列番号107として示すアミノ酸配列を含んでおり;
L-CDR2は、配列番号109として示すアミノ酸配列を含んでおり;
L-CDR3は、配列番号111として示すアミノ酸配列を含んでいる抗体または抗原結合フラグメントが提供される。
H-CDR1は、配列番号9として示すアミノ酸配列を含んでおり;
H-CDR2は、配列番号11として示すアミノ酸配列を含んでおり;
H-CDR3は、配列番号13として示すアミノ酸配列を含んでおり;
L-CDR1は、配列番号86として示すアミノ酸配列を含んでおり;
L-CDR2は、配列番号88として示すアミノ酸配列を含んでおり;
L-CDR3は、配列番号90として示すアミノ酸配列を含んでいる抗体または抗原結合フラグメントが提供される。
(i)MET受容体のリン酸化。この文脈では、METアゴニスト抗体またはMETアゴニスト抗原結合フラグメントは、受容体-リガンドの結合の不在下でこの抗体または抗原結合フラグメントの結合によってMETの自己リン酸化が起こる場合に、METをリン酸化する。すなわちこの抗体または抗原結合フラグメントは、hHGFの不在下でヒトhMETに結合してhMETをリン酸化し、この抗体または抗原結合フラグメントは、mHGFの不在下でmMETに結合してmMETをリン酸化する。METのリン酸化は、本分野で知られているアッセイ(例えば(実施例6とBasilico他、J Clin Invest. 第124巻、3172~3186ページ、2014年に記載されている)ウエスタンブロッティングやホスホ-MET ELISA)によって明らかにすることができる。本明細書に記載した抗体と抗原結合フラグメントは、hMETに対して「大きなリン酸化効力」または「小さなリン酸化効力」を示すとともに、mMETに対して「大きなリン酸化効力」または「小さなリン酸化効力」を示す可能性がある。この文脈では、抗体または抗原結合フラグメントは、この抗体またはフラグメントが、mMETに対して、HGFに対するのと同様のEC50(<1 nM)および/または少なくとも80%の(HGFによって誘導される最大活性化に対する割合としての)EMAXという効力を示し、hMETに対して、HGFに対するのと同様のEC50(<1 nM)および/または少なくとも80%の(HGFによって誘導される最大活性化に対する割合としての)EMAXという効力を示す場合に、「大きなリン酸化効力」を示している。抗体または抗原結合フラグメントは、この抗体またはフラグメントが、mMETに対して1 nM~5 nMのEC50および/または60~80%の(HGFによって誘導される最大活性化に対する割合としての)EMAXという効力を示し、hMETに対して1 nM~5 nMのEC50および/または60~80%の(HGFによって誘導される最大活性化に対する割合としての)EMAXという効力を示す場合に、「小さなリン酸化効力」を示している。
(ii)HGF様細胞応答の誘導。MET活性化作用は、本明細書の実施例に記載した細胞散乱アッセイ、および/または抗アポトーシスアッセイ、および/または分岐形態形成アッセイといったアッセイを利用して測定することができる。この文脈では、本発明によるMETアゴニスト抗体またはMETアゴニスト抗原結合フラグメントは、細胞アッセイにおいて、例えば相同なHGFに曝露した後に観察される応答と(少なくとも部分的に)似た応答を誘導する。例えばMETアゴニストであることは、対照抗体(例えばIgG1)に曝露した細胞と比べてこの抗体に応答した細胞散乱の増加が見られること;および/または、薬によって誘導されるアポトーシスからの保護効力が、32 nM未満のEC50および/または処理していない細胞と比べて20%超大きなEMAX細胞生存率であること;および/または、この抗体または抗原結合フラグメントに曝露した細胞スフェロイド調製物の中のスフェロイド当たりの分岐の数が増加することによって示すことができる。
細胞散乱アッセイにおいて、抗体または抗原結合フラグメントが、濃度0.1~1 nMで、0.1 nMの相同なHGFと少なくとも同等な細胞散乱の増加を誘導する;および/または
抗アポトーシスアッセイにおいて、抗体または抗原結合フラグメントが、HGFの値の1.1倍以下のEC50および/またはHGFで観察される値の90%超のEMAX細胞生存率を示す;および/または
分岐形態形成アッセイにおいて、抗体または抗原結合フラグメントで処理した細胞が、同じ(ゼロではない)濃度のHGFによって誘導されるスフェロイド当たりの分岐の数の90%超を示す。
細胞散乱アッセイにおいて、抗体または抗原結合フラグメントが、1 nM以下の濃度で、0.1 nMの相同なHGFによって誘導される値の少なくとも25%のレベルの細胞散乱を誘導する;
抗アポトーシスアッセイにおいて、抗体または抗原結合フラグメントが、HGFの値の7.0倍以下のEC50および/またはHGFで観察される値の少なくとも50%のEMAX細胞生存率を示す;
分岐形態形成アッセイにおいて、抗体または抗原結合フラグメントで処理した細胞が、同じ(ゼロではない)濃度のHGFによって誘導されるスフェロイド当たりの分岐の数の少なくとも25%を示す。
1)ラクダ科のVHドメインおよびVLドメインとの大きな%配列相同性;
2)ラクダ科のVHドメインとVLドメインのCDRと、ヒトでの対応物(すなわち、ヒト様標準的折り畳み構造と、標準的折り畳みのヒト様組み合わせ)との間の大きな構造相同性
が理由で、ヒト治療剤として有用な抗体を調製するための有利な出発点を提供する。ラクダ科(例えばラマ)のプラットフォームも、取得できるMET抗体の機能の多様性に関して大きな利点を提供することができる。
Anstee QM and Goldin RD, Int J Exp Pathol. 87, 1-16, 2006
Basilico C et al, J Biol. Chem. 283:21267-21227, 2008
Basilico C et al., J Clin Invest. 124, 3172-3186, 2014
Cassano M et al., PLoS One 3, e3223, 2008
Chomczynski P et al., Anal. Biochem. 162:156-159, 1987
Daley LP et al., Clin. Vaccine Immunol. 12, 2005
de Haard H et al., J Biol Chem. 274:18218-18230, 1999
De Haard H et al., J. Bact. 187:4531-4541, 2005
Fafalios A et al. Nat Med. 17, 1577-1584, 2011
Forte G et al., Stem Cells. 24, 23-33, 2006
Hultberg A et al., Cancer Res. 75, 3373-3383, 2015
Ido A et al., Hepatol Res. 30, 175-181, 2004
Jones-Hall YL and Grisham MB, Pathophysiology 21, 267-288, 2014
Kim JJ et al., J Vis Exp. 60, pii: 3678, 2012
Kosone T et al., Am J Physiol Gastrointest Liver Physiol. 293, G204-210, 2007
Kroy DC et al. J Hepatol. 61, 883-890, 2014
Longati P et al., Oncogene 9, 49-57, 1994
Matsumoto K and Nakamura T, Ciba Found Symp. 212, 198-214, 1997
Medico E et al., Mol Biol Cell 7, 495-504, 1996
Merchant M et al., Proc Natl Acad Sci USA 110, E2987-2996, 2013
Michieli P et al. Nat Biotechnol. 20, 488-495, 2002
Mizuno S et al. Front Biosci. 13, 7072-7086, 2008
Nakamura T et al., J Gastroenterol Hepatol. 26 Suppl 1, 188-202, 2011
Perdomo G et al., J Biol Chem. 283, 13700-13706, 2008
Petrelli A et al., Proc Natl Acad Sci USA 103, 5090-9095, 2006
Pietronave S et al., Am J Physiol Heart Circ Physiol. 298, H1155-65, 2010
Prat M et al., Mol Cell Biol. 11, 5954-5962, 1991
Prat M et al., J Cell Sci. 111, 237-247, 1998
Rosario M and Birchmeier W, Trends Cell Biol. 13, 328-335, 2003
Stamos J et al., EMBO J. 23, 2325-2335, 2004
Takahara et al., Hepatology, 47, 2010-2025, 2008
Wang B et al. Curr Diabetes Rev. 10, 131-145, 2014
Claims (60)
- ヒトMETタンパク質(hMET)に大きな親和性で結合するとともにマウスMETタンパク質(mMET)に大きな親和性で結合し、hMETアゴニストかつmMETアゴニストである、抗体またはその抗原結合フラグメント。
- 少なくとも1つの重鎖可変ドメイン(VH)と、少なくとも1つの軽鎖可変ドメイン(VL)を含んでいて、そのVHドメインとVLドメインが、Fabフラグメントとして試験するとき、hMETに対して1×10-3/秒~1×10-2/秒の範囲、場合によっては1×10-3/秒~6×10-3/秒の範囲のオフレート(Biacoreによって測定されるkoff)を示すとともに、mMETに対して1×10-3/秒~1×10-2/秒の範囲、場合によっては1×10-3/秒~6×10-3/秒の範囲のオフレート(Biacoreによって測定されるkoff)を示す、請求項1に記載の抗体またはその抗原結合フラグメント。
- hMETとmMETに対して同等の親和性を有する、請求項1または2に記載の抗体またはその抗原結合フラグメント。
- hMETのリン酸化を誘導するとともに、mMETのリン酸化を誘導する、請求項1~4のいずれか1項に記載の抗体またはその抗原結合フラグメント。
- hMETのリン酸化を3.0 nM未満、場合によっては2.0 nM未満の(ホスホ-MET ELISAによって測定される)EC50で誘導するとともに、mMETのリン酸化を3.0 nM未満、場合によっては2.0 nM未満の(ホスホ-MET ELISAによって測定される)EC50で誘導する、請求項4に記載の抗体またはその抗原結合フラグメント。
- hMETのリン酸化とmMETのリン酸化を同等に誘導する、請求項4または5に記載の抗体またはその抗原結合フラグメント。
- hMETに対して大きなリン酸化効力を示すとともに、mMETに対して大きなリン酸化効力を示す、請求項4~6のいずれか1項に記載の抗体またはその抗原結合フラグメント。
- hMETのリン酸化を1 nM未満のEC50および/または少なくとも80%の(ホスホ-MET ELISAにおいてHGCによって誘導される活性化の割合としての)Emaxで誘導するとともに、mMETのリン酸化を1 nM未満のEC50および/または少なくとも80%の(ホスホ-MET ELISAにおいてHGCによって誘導される活性化の割合としての)Emaxで誘導する、請求項7に記載の抗体またはその抗原結合フラグメント。
- hMETに対して小さなリン酸化効力を示すとともに、mMETに対して小さなリン酸化効力を示す、請求項1~6のいずれか1項に記載の抗体またはその抗原結合フラグメント。
- hMETのリン酸化を1 nM~5 nMのEC50および/または60~80%の(ホスホ-MET ELISAにおいてHGCによって誘導される活性化の割合としての)Emaxで誘導するとともに、mMETのリン酸化を1 nM~5 nMのEC50および/または60~80%の(ホスホ-MET ELISAにおいてHGCによって誘導される活性化の割合としての)Emaxで誘導する、請求項9に記載の抗体またはその抗原結合フラグメント。
- ヒト細胞と接触したときにHGF様細胞応答を誘導するとともに、マウス細胞と接触したときにHGF様細胞応答を誘導する、請求項1~10のいずれか1項に記載の抗体またはその抗原結合フラグメント。
- ヒト細胞と接触したときとマウス細胞と接触したときにHGF様細胞応答を全面的に誘導する、請求項11に記載の抗体またはその抗原結合フラグメント。
- HGF様細胞応答の全面的な誘導が、
(i)細胞散乱アッセイにおいて、濃度が0.1~1.0 nMのとき、HGFが誘導する最大の散乱に匹敵する細胞散乱を誘導すること;および/または
(ii)抗アポトーシス細胞アッセイにおいて、HGFの値の1.1倍未満のEC50および/またはHGFで観察される値の90%超のEmax(非アポトーシス対照細胞の全ATP含量に対する%として測定される)を示すこと、および/または;
(iii)分岐形態形成アッセイにおいて、抗体で処理した細胞が、同じ(ゼロでない)濃度のHGFによって誘導されるスフェロイド当たりの分岐の数の90%超を示すこと
のうちの1つ、または任意の2つ、またはすべてとして測定可能である、請求項11または12に記載の抗体またはその抗原結合フラグメント。 - ヒト細胞と接触したときとマウス細胞と接触したときにHGF様細胞応答を部分的に誘導する、請求項11に記載の抗体またはその抗原結合フラグメント。
- HGF様細胞応答の部分的な誘導が、
(i)細胞散乱アッセイにおいて、濃度が1 nM以下のとき、0.1 nMの相同なHGFによって誘導される値の少なくとも25%の細胞散乱を誘導すること;および/または
(ii)抗アポトーシス細胞アッセイにおいて、HGFの値の7.0倍以下のEC50および/またはHGFで観察される値の少なくとも50%のEmax細胞生存率を示すこと;および/または
(iii)分岐形態形成アッセイにおいて、抗体で処理した細胞が、同じ(ゼロでない)濃度のHGFによって誘導されるスフェロイド当たりの分岐の数の少なくとも25%を示すこと
として測定可能である、請求項14に記載の抗体またはその抗原結合フラグメント。 - HGF競合体である、請求項1~15のいずれか1項に記載の抗体またはその抗原結合フラグメント。
- 5 nM以下のIC50および/または少なくとも50%のImaxでhMETへの結合をhHGFと競合するとともに、5 nM以下のIC50および/または少なくとも50%のImaxでmMETへの結合をmHGFと競合する、請求項16に記載の抗体またはその抗原結合フラグメント。
- hHGFおよびmHGFと同等に競合する、請求項16または17に記載の抗体またはその抗原結合フラグメント。
- 全面的なHGF競合体である、請求項16~18のいずれか1項に記載の抗体またはその抗原結合フラグメント。
- 2 nM未満のIC50および/または90%超のImaxでhHGFと競合するとともに、2 nM未満のIC50および/または90%超のImaxでmHGFと競合する、請求項19に記載の抗体またはその抗原結合フラグメント。
- 部分的なHGF競合体である、請求項16~18のいずれか1項に記載の抗体またはその抗原結合フラグメント。
- 2~5 nMのIC50および/または50%~90%のImaxでhHGFと競合するとともに、2~5 nMのIC50および/または50%~90%のImaxでmHGFと競合する、請求項21に記載の抗体またはその抗原結合フラグメント。
- ヒトMETのアミノ酸残基123~残基223、またはヒトMETのアミノ酸残基224~残基311、またはヒトMETのアミノ酸残基314~残基372、またはヒトMETのアミノ酸残基546~残基562の領域内に位置するヒトMETのエピトープを認識する抗体またはその抗原結合フラグメント。
- METの細胞外ドメインの中にあってヒトMETとマウスMETで保存されている1個以上のアミノ酸を含むエピトープを認識する抗体またはその抗原結合フラグメント。
- ヒトMETのアミノ酸残基Ile367および/またはAsp372を含んでいて、場合によってはヒトMETのアミノ酸残基314~残基372の領域内に位置するヒトMETのエピトープを認識する抗体またはその抗原結合フラグメント。
- ヒトMETのアミノ酸残基Thr555を含んでいて、場合によってはヒトMETのアミノ酸残基546~残基562の領域内に位置するヒトMETのエピトープを認識する抗体またはその抗原結合フラグメント。
- H-CDR1、H-CDR2、H-CDR3を含む重鎖可変ドメインと、L-CDR1、L-CDR2、L-CDR3を含む軽鎖可変ドメインを含んでいて、その中の
H-CDR1は、配列番号2、9、16、23、30、37、44、51、58、65、72から選択されたアミノ酸配列を含んでおり;
H-CDR2は、配列番号4、11、18、25、32、39、46、53、60、67、74から選択されたアミノ酸配列を含んでおり;
H-CDR3は、配列番号6、13、20、27、34、41、48、55、62、69、76から選択されたアミノ酸配列を含んでおり;
L-CDR1は、配列番号79、86、93、100、107、114、121、128、135、142、149から選択されたアミノ酸配列を含んでおり;
L-CDR2は、配列番号81、88、95、102、109、116、123、130、137、144、151から選択されたアミノ酸配列を含んでおり;
L-CDR3は、配列番号83、90、97、104、111、118、125、132、139、146、153から選択されたアミノ酸配列を含んでいる抗体またはその抗原結合フラグメント。 - 請求項1~22のいずれか1項に記載の抗体またはその抗原結合フラグメントである、請求項23~27のいずれか1項に記載の抗体。
- [71G2]H-CDR1、H-CDR2、H-CDR3を含む重鎖可変ドメインと、L-CDR1、L-CDR2、L-CDR3を含む軽鎖可変ドメインを含んでいて、その中の
H-CDR1は、配列番号44として示すアミノ酸配列を含んでおり;
H-CDR2は、配列番号46として示すアミノ酸配列を含んでおり;
H-CDR3は、配列番号48として示すアミノ酸配列を含んでおり;
L-CDR1は、配列番号121として示すアミノ酸配列を含んでおり;
L-CDR2は、配列番号123として示すアミノ酸配列を含んでおり;
L-CDR3は、配列番号125として示すアミノ酸配列を含んでいる抗体またはその抗原結合フラグメント。 - [71G2]前記重鎖可変ドメインが、配列番号167のアミノ酸配列を含むか、その配列と少なくとも90%、または95%、または97%、または99%一致する配列を含むとともに、前記軽鎖可変ドメインが、配列番号168のアミノ酸配列を含むか、その配列と少なくとも90%、または95%、または97%、または99%一致する配列を含む、請求項23に記載の抗体またはその抗原結合フラグメント。
- 請求項1~22のいずれか1項に記載の抗体またはその抗原結合フラグメントである、請求項29または30に記載の抗体またはその抗原結合フラグメント。
- [71D6]H-CDR1、H-CDR2、H-CDR3を含む重鎖可変ドメインと、L-CDR1、L-CDR2、L-CDR3を含む軽鎖可変ドメインを含んでいて、その中の
H-CDR1は、配列番号30として示すアミノ酸配列を含んでおり;
H-CDR2は、配列番号32として示すアミノ酸配列を含んでおり;
H-CDR3は、配列番号34として示すアミノ酸配列を含んでおり;
L-CDR1は、配列番号107として示すアミノ酸配列を含んでおり;
L-CDR2は、配列番号109として示すアミノ酸配列を含んでおり;
L-CDR3は、配列番号111として示すアミノ酸配列を含んでいる抗体または抗原結合フラグメント。 - [71D6]前記重鎖可変ドメインが、配列番号163のアミノ酸配列を含むか、その配列と少なくとも90%、または95%、または97%、または99%一致する配列を含むとともに、前記軽鎖可変ドメインが、配列番号164のアミノ酸配列を含むか、その配列と少なくとも90%、または95%、または97%、または99%一致する配列を含む、請求項25に記載の抗体またはその抗原結合フラグメント。
- 請求項1~22のいずれか1項に記載の抗体またはその抗原結合フラグメントである、請求項32または33に記載の抗体またはその抗原結合フラグメント。
- [71G3]H-CDR1、H-CDR2、H-CDR3を含む重鎖可変ドメインと、L-CDR1、L-CDR2、L-CDR3を含む軽鎖可変ドメインを含んでいて、
H-CDR1は、配列番号9として示すアミノ酸配列を含んでおり;
H-CDR2は、配列番号11として示すアミノ酸配列を含んでおり;
H-CDR3は、配列番号13として示すアミノ酸配列を含んでおり;
L-CDR1は、配列番号86として示すアミノ酸配列を含んでおり;
L-CDR2は、配列番号88として示すアミノ酸配列を含んでおり;
L-CDR3は、配列番号90として示すアミノ酸配列を含んでいる抗体または抗原結合フラグメント。 - [71G3]前記重鎖可変ドメインが、配列番号157のアミノ酸配列を含むか、その配列と少なくとも90%、または95%、または97%、または99%一致する配列を含むとともに、前記軽鎖可変ドメインが、配列番号158のアミノ酸配列を含むか、その配列と少なくとも90%、または95%、または97%、または99%一致する配列を含む、請求項27に記載の抗体またはその抗原結合フラグメント。
- 請求項1~22のいずれか1項に記載の抗体またはその抗原結合フラグメントである、請求項35または36に記載の抗体またはその抗原結合フラグメント。
- 請求項1~37のいずれか1項に記載の抗体または抗原結合フラグメントの親和性バリアントまたはヒト生殖系列化バリアント。
- ヒトIgGのヒンジ領域、場合によってはIgG1のヒンジ領域、および/またはCH2ドメイン、および/またはCH3ドメインを含有する、請求項1~38のいずれか1項に記載の抗体または抗原結合フラグメント。
- ヒトIgGと、好ましくはIgG1と少なくとも90%、または95%、または97%、または99%一致する配列を持つCH2および/またはCH3ドメインを含み、場合によってはそのCH2および/またはCH3ドメインが改変されて、1つ以上の抗体エフェクタ機能が低下するか実質的に消えている、請求項1~39のいずれか1項に記載の抗体。
- 前記VHドメインおよび/またはVLドメイン、またはCDRの1つ以上がラクダ科の動物に由来する、請求項1~40のいずれか1項に記載の抗体または抗原結合フラグメント。
- 前記動物がラマである、請求項41に記載の抗体または抗原結合フラグメント。
- 請求項1~40のいずれか1項に記載の抗体または抗原結合フラグメントをコードする単離されたポリヌクレオチド。
- 宿主細胞または無細胞発現系の中で前記抗体または抗原結合フラグメントの発現を可能にする調節配列に機能可能に連結された請求項43に記載のポリヌクレオチドを含む発現ベクター。
- 請求項44に記載の発現ベクターを含有する宿主細胞または無細胞発現系。
- 組み換え抗体またはその抗原結合フラグメントを作製する方法であって、その抗体または抗原結合フラグメントの発現を可能にする条件下で請求項45の宿主細胞または無細胞発現系を培養し、発現した抗体または抗原結合フラグメントを回収することを含む方法。
- 請求項1~42のいずれか1項に記載の抗体または抗原結合フラグメントと、医薬として許容可能な基剤または賦形剤を含む医薬組成物。
- 治療で利用するための、請求項1~42のいずれか1項に記載の抗体または抗原結合フラグメント、または請求項47に記載の医薬組成物。
- ヒト患者で肝障害、場合によっては急性肝障害を治療または予防する方法であって、それを必要とする患者にMETアゴニスト抗体の治療に有効な量を投与することを含む方法。
- 前記METアゴニスト抗体が、請求項1~42のいずれか1項に記載の抗体または抗原結合フラグメントである、請求項49に記載の方法。
- ヒト患者で腎損傷、場合によっては急性腎損傷を治療または予防する方法であって、それを必要とする患者にMETアゴニスト抗体の治療に有効な量を投与することを含む方法。
- 前記METアゴニスト抗体が、請求項1~42のいずれか1項に記載の抗体または抗原結合フラグメントである、請求項51に記載の方法。
- ヒト患者で炎症性腸疾患、場合によっては潰瘍性大腸炎を治療または予防する方法であって、それを必要とする患者にMETアゴニスト抗体の治療に有効な量を投与することを含む方法。
- 前記METアゴニスト抗体が、請求項1~42のいずれか1項に記載の抗体または抗原結合フラグメントである、請求項53に記載の方法。
- ヒト患者で糖尿病、場合によってはI型またはII型の糖尿病を治療または予防する方法であって、それを必要とする患者にMETアゴニスト抗体の治療に有効な量を投与することを含む方法。
- 前記METアゴニスト抗体が、請求項1~42のいずれか1項に記載の抗体または抗原結合フラグメントである、請求項55に記載の方法。
- ヒト患者で非アルコール性脂肪性肝炎を治療または予防する方法であって、それを必要とする患者にMETアゴニスト抗体の治療に有効な量を投与することを含む方法。
- 前記METアゴニスト抗体が、請求項1~42のいずれか1項に記載の抗体または抗原結合フラグメントである、請求項57に記載の方法。
- ヒト患者、場合によっては糖尿病を持つ患者で傷の治癒を治療または促進する方法であって、それを必要とする患者にMETアゴニスト抗体の治療に有効な量を投与することを含む方法。
- 前記METアゴニスト抗体が、請求項1~42のいずれか1項に記載の抗体または抗原結合フラグメントである、請求項59に記載の方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1611123.9A GB201611123D0 (en) | 2016-06-27 | 2016-06-27 | Anti met antibodiesand uses thereof |
GB1611123.9 | 2016-06-27 | ||
JP2018569021A JP7088853B2 (ja) | 2016-06-27 | 2017-06-23 | 抗met抗体とその利用 |
PCT/EP2017/065599 WO2018001909A1 (en) | 2016-06-27 | 2017-06-23 | Anti-met antibodies and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018569021A Division JP7088853B2 (ja) | 2016-06-27 | 2017-06-23 | 抗met抗体とその利用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022121461A true JP2022121461A (ja) | 2022-08-19 |
Family
ID=56891586
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018569021A Active JP7088853B2 (ja) | 2016-06-27 | 2017-06-23 | 抗met抗体とその利用 |
JP2022093880A Pending JP2022121461A (ja) | 2016-06-27 | 2022-06-09 | 抗met抗体とその利用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018569021A Active JP7088853B2 (ja) | 2016-06-27 | 2017-06-23 | 抗met抗体とその利用 |
Country Status (12)
Country | Link |
---|---|
US (2) | US11098126B2 (ja) |
EP (2) | EP3674321A3 (ja) |
JP (2) | JP7088853B2 (ja) |
KR (3) | KR102566845B1 (ja) |
CN (2) | CN109689687B (ja) |
AU (1) | AU2017288985B2 (ja) |
BR (1) | BR112018077139A8 (ja) |
CA (1) | CA3032496A1 (ja) |
GB (1) | GB201611123D0 (ja) |
MX (1) | MX2019000135A (ja) |
RU (2) | RU2022101369A (ja) |
WO (1) | WO2018001909A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
IT201800000534A1 (it) * | 2018-01-03 | 2019-07-03 | Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici. | |
IT201800000535A1 (it) * | 2018-01-03 | 2019-07-03 | Procedimenti per la cura del cancro. | |
KR102221755B1 (ko) * | 2018-05-02 | 2021-03-02 | (주)에임드바이오 | c-Met에 특이적으로 결합하는 항체 및 그의 용도 |
SG11202108311RA (en) | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
JOP20210304A1 (ar) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث |
BR112023020801A2 (pt) | 2021-04-08 | 2023-12-12 | Byondis Bv | Anticorpo ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação de um anticorpo ou fragmento de ligação ao antígeno, um conjugado anticorpo-fármaco ou uma composição farmacêutica |
CA3219754A1 (en) | 2021-05-21 | 2022-11-24 | Gary Beale | Microwave treatment of tissue |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000515735A (ja) * | 1996-07-03 | 2000-11-28 | ジェネンテック インコーポレーテッド | 肝細胞成長因子レセプターアゴニスト |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
GB0110430D0 (en) * | 2001-04-27 | 2001-06-20 | Medical Res Council | Protein variants and uses thereof |
ITMI20031127A1 (it) | 2003-06-05 | 2004-12-06 | Uni Degli Studi Del Piemont E Orientale Am | Anticorpi anti-hgf-r e loro uso |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
PT1773885E (pt) * | 2004-08-05 | 2010-07-21 | Genentech Inc | Antagonistas anti-cmet humanizados |
KR101429297B1 (ko) | 2006-02-06 | 2014-08-12 | 메테레시스 트랜스레이셔날 리서치 에스.에이. | 종양 치료를 위한 항-Met 단클론 항체, 이의 단편과벡터 및 상응하는 산물 |
AU2011203499B2 (en) * | 2006-03-30 | 2013-01-31 | Novartis Ag | Compositions and methods of use for antibodies of c-Met |
GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
US9169329B2 (en) | 2010-06-01 | 2015-10-27 | Ludwig Institute For Cancer Research | Antibodies directed to the receptor tyrosine kinase c-Met |
JP5857060B2 (ja) * | 2010-11-03 | 2016-02-10 | アルゲン−エックス エヌ.ブイ. | 抗c−Met抗体 |
CN103582490B (zh) | 2011-04-02 | 2015-09-30 | 华盛顿州立大学 | 作为治疗剂的肝细胞生长因子模拟物 |
KR101444837B1 (ko) * | 2011-06-03 | 2014-09-30 | 한국생명공학연구원 | HGF 활성을 가지는 c-Met에 대한 인간항체 및 이의 용도 |
GB201121914D0 (en) * | 2011-12-20 | 2012-02-01 | Ge Healthcare Ltd | Method for patient selection |
KR101615619B1 (ko) | 2014-08-07 | 2016-04-26 | 주식회사 파멥신 | c-Met 특이적 인간 항체 및 그 제조방법 |
EP3237450B1 (en) | 2014-12-22 | 2021-03-03 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
ES2896709T3 (es) | 2016-02-05 | 2022-02-25 | Helixmith Co Ltd | Anticuerpos anti-c-Met y usos de los mismos |
IT201800000534A1 (it) | 2018-01-03 | 2019-07-03 | Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici. | |
GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
IT201800000535A1 (it) | 2018-01-03 | 2019-07-03 | Procedimenti per la cura del cancro. |
-
2016
- 2016-06-27 GB GBGB1611123.9A patent/GB201611123D0/en not_active Ceased
-
2017
- 2017-06-23 KR KR1020227005547A patent/KR102566845B1/ko active IP Right Grant
- 2017-06-23 US US16/313,710 patent/US11098126B2/en active Active
- 2017-06-23 KR KR1020237027102A patent/KR20230120678A/ko active IP Right Grant
- 2017-06-23 KR KR1020197002631A patent/KR102366667B1/ko active IP Right Grant
- 2017-06-23 RU RU2022101369A patent/RU2022101369A/ru unknown
- 2017-06-23 MX MX2019000135A patent/MX2019000135A/es unknown
- 2017-06-23 RU RU2018146419A patent/RU2765267C2/ru active
- 2017-06-23 CN CN201780040456.2A patent/CN109689687B/zh active Active
- 2017-06-23 EP EP19202060.0A patent/EP3674321A3/en active Pending
- 2017-06-23 CN CN202210749235.5A patent/CN115057933A/zh active Pending
- 2017-06-23 AU AU2017288985A patent/AU2017288985B2/en active Active
- 2017-06-23 JP JP2018569021A patent/JP7088853B2/ja active Active
- 2017-06-23 WO PCT/EP2017/065599 patent/WO2018001909A1/en unknown
- 2017-06-23 EP EP17735419.8A patent/EP3475302A1/en active Pending
- 2017-06-23 BR BR112018077139A patent/BR112018077139A8/pt unknown
- 2017-06-23 CA CA3032496A patent/CA3032496A1/en active Pending
-
2021
- 2021-08-09 US US17/397,510 patent/US20220153850A1/en active Pending
-
2022
- 2022-06-09 JP JP2022093880A patent/JP2022121461A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000515735A (ja) * | 1996-07-03 | 2000-11-28 | ジェネンテック インコーポレーテッド | 肝細胞成長因子レセプターアゴニスト |
Also Published As
Publication number | Publication date |
---|---|
WO2018001909A1 (en) | 2018-01-04 |
KR20220030306A (ko) | 2022-03-10 |
RU2018146419A (ru) | 2020-06-26 |
KR20230120678A (ko) | 2023-08-17 |
BR112018077139A8 (pt) | 2022-12-13 |
RU2022101369A (ru) | 2022-02-08 |
AU2017288985A1 (en) | 2019-01-17 |
GB201611123D0 (en) | 2016-08-10 |
AU2017288985B2 (en) | 2024-05-16 |
CN109689687A (zh) | 2019-04-26 |
EP3475302A1 (en) | 2019-05-01 |
EP3674321A3 (en) | 2020-09-30 |
RU2018146419A3 (ja) | 2020-09-30 |
CN115057933A (zh) | 2022-09-16 |
BR112018077139A2 (pt) | 2019-04-30 |
US11098126B2 (en) | 2021-08-24 |
KR20190025938A (ko) | 2019-03-12 |
JP7088853B2 (ja) | 2022-06-21 |
JP2019524085A (ja) | 2019-09-05 |
KR102366667B1 (ko) | 2022-02-23 |
US20220153850A1 (en) | 2022-05-19 |
RU2765267C2 (ru) | 2022-01-27 |
CN109689687B (zh) | 2022-07-15 |
KR102566845B1 (ko) | 2023-08-14 |
EP3674321A2 (en) | 2020-07-01 |
US20190315873A1 (en) | 2019-10-17 |
MX2019000135A (es) | 2019-09-26 |
CA3032496A1 (en) | 2018-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022121461A (ja) | 抗met抗体とその利用 | |
BR122014027420A2 (pt) | Anticorpos anti c-met | |
KR20160131061A (ko) | 항-mcam 항체 및 관련된 사용 방법 | |
JP2024008945A (ja) | 膵島細胞の増殖を促進する方法 | |
US20200407452A1 (en) | Methods for promoting pancreatic islet cell growth | |
US11834507B2 (en) | Anti-MET agonist antibody for use in the treatment of colorectal cancer | |
US20240132601A1 (en) | Anti-met antibodies and uses thereof | |
CN116391041A (zh) | 一种含抗***生长因子抗体的药物组合物 | |
NZ789725A (en) | Anti-met antibodies and uses thereof | |
NZ789721A (en) | Anti-met antibodies and uses thereof | |
NZ789717A (en) | Anti-met antibodies and uses thereof | |
WO2023074888A1 (ja) | 新規なNav1.7モノクローナル抗体 | |
NZ789715A (en) | Anti-met antibodies and uses thereof | |
Michieli | HGF-MET AGONIST FOR USE IN THE TREATMENT OF CANCER AND COLORECTAL FIBROSIS | |
CN111787980A (zh) | 非酒精性脂肪性肝炎的抗huTNFR1疗法 | |
JP2022523750A (ja) | 抗-fgf19抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220622 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220622 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230613 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240502 |